PDF(Pubmed)
Abstract：
UNASSIGNED: This study aimed to investigate the usefulness of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for diagnosing focal liver lesions in patients with a history of multiple primary malignant neoplasms.
UNASSIGNED: Among patients who underwent EUS-TA for focal liver lesions between 2016 and 2022, those with a history of multiple malignant neoplasms were included. A histologically confirmed malignant tumor within the past 5 years before EUS-TA was defined as a history of malignant neoplasm. The primary outcomes were diagnostic ability and adverse events of EUS-TA.
UNASSIGNED: This study included 16 patients (median age, 73 [33-90] years), the median tumor size was 32 (6-51) mm, 14 had a history of double malignant neoplasms, whereas two had triple malignant neoplasms. Malignant neoplasms were detected histologically or cytologically in all cases. Immunohistochemistry was performed in 75% (12/16), and the final diagnosis of EUS-TA was metastatic liver tumor in 12 patients, and primary malignant liver tumor in four patients. The primary site could be identified in 11 of 12 metastatic tumor cases. The diagnostic yield of EUS-TA was 100% (16/16) for differentiating benign and malignant tumors and 94% (15/16) for confirming the histological type including the primary site of metastatic lesions. No adverse events were associated with the procedure.
UNASSIGNED: EUS-TA is a useful diagnostic modality for focal liver lesions in patients with a history of multiple malignant neoplasms, allowing for the differential diagnosis of primary and metastatic tumors and identification of the primary site of metastatic lesions.
UNASSIGNED: Among patients who underwent EUS-TA for focal liver lesions between 2016 and 2022, those with a history of multiple malignant neoplasms were included. A histologically confirmed malignant tumor within the past 5 years before EUS-TA was defined as a history of malignant neoplasm. The primary outcomes were diagnostic ability and adverse events of EUS-TA.
UNASSIGNED: This study included 16 patients (median age, 73 [33-90] years), the median tumor size was 32 (6-51) mm, 14 had a history of double malignant neoplasms, whereas two had triple malignant neoplasms. Malignant neoplasms were detected histologically or cytologically in all cases. Immunohistochemistry was performed in 75% (12/16), and the final diagnosis of EUS-TA was metastatic liver tumor in 12 patients, and primary malignant liver tumor in four patients. The primary site could be identified in 11 of 12 metastatic tumor cases. The diagnostic yield of EUS-TA was 100% (16/16) for differentiating benign and malignant tumors and 94% (15/16) for confirming the histological type including the primary site of metastatic lesions. No adverse events were associated with the procedure.
UNASSIGNED: EUS-TA is a useful diagnostic modality for focal liver lesions in patients with a history of multiple malignant neoplasms, allowing for the differential diagnosis of primary and metastatic tumors and identification of the primary site of metastatic lesions.
摘要：
■本研究旨在探讨内镜超声引导组织采集（EUS-TA）对有多原发恶性肿瘤病史的患者局灶性肝脏病变的诊断价值。
■在2016年至2022年期间接受EUS-TA治疗局灶性肝脏病变的患者中，包括有多发性恶性肿瘤病史的患者。在EUS-TA被定义为恶性肿瘤病史之前的过去5年内，经组织学证实的恶性肿瘤。主要结果是EUS-TA的诊断能力和不良事件。
■这项研究包括16名患者(中位年龄，73[33-90]年），中位肿瘤大小为32（6-51）mm，14人有双重恶性肿瘤史，而两个有三个恶性肿瘤。在所有病例中均在组织学或细胞学上检测到恶性肿瘤。在75%（12/16）中进行了免疫组织化学，EUS-TA的最终诊断为12例转移性肝肿瘤，4例原发性肝脏恶性肿瘤。在12例转移性肿瘤病例中，有11例可以确定原发部位。EUS-TA用于区分良性和恶性肿瘤的诊断率为100％（16/16），用于确认组织学类型（包括转移灶的原发部位）的诊断率为94％（15/16）。没有不良事件与手术相关。
■EUS-TA是有多发性恶性肿瘤病史的患者肝脏局灶性病变的一种有用的诊断方法。允许对原发性和转移性肿瘤进行鉴别诊断，并确定转移性病变的原发部位。
■在2016年至2022年期间接受EUS-TA治疗局灶性肝脏病变的患者中，包括有多发性恶性肿瘤病史的患者。在EUS-TA被定义为恶性肿瘤病史之前的过去5年内，经组织学证实的恶性肿瘤。主要结果是EUS-TA的诊断能力和不良事件。
■这项研究包括16名患者(中位年龄，73[33-90]年），中位肿瘤大小为32（6-51）mm，14人有双重恶性肿瘤史，而两个有三个恶性肿瘤。在所有病例中均在组织学或细胞学上检测到恶性肿瘤。在75%（12/16）中进行了免疫组织化学，EUS-TA的最终诊断为12例转移性肝肿瘤，4例原发性肝脏恶性肿瘤。在12例转移性肿瘤病例中，有11例可以确定原发部位。EUS-TA用于区分良性和恶性肿瘤的诊断率为100％（16/16），用于确认组织学类型（包括转移灶的原发部位）的诊断率为94％（15/16）。没有不良事件与手术相关。
■EUS-TA是有多发性恶性肿瘤病史的患者肝脏局灶性病变的一种有用的诊断方法。允许对原发性和转移性肿瘤进行鉴别诊断，并确定转移性病变的原发部位。
